European Union - English - EMA (European Medicines Agency)

stada arzneimittel ag - teriparatide - osteoporosis - calcium homeostasis - movymia is indicated in adults.treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. in postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

European Union - English - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv)

European Union - English - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastic agents - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. for further information as to human epidermal growth factor receptor 2 (her2) status, please refer to section 5.1.oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. for further information as to her2 status, please refer to section 5.1.oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology.oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5.1).oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents.oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5.1).oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - quetiapine - prolonged-release tablet - 50 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine - antipsychotics; diazepines, oxazepines, thiazepines and oxepines - it is indicated for: treatment of schizophrenia; treatment of bipolar disorder; add-on treatment of major depressive episodes in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - quetiapine - prolonged-release tablet - 150 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine - antipsychotics; diazepines, oxazepines, thiazepines and oxepines - it is indicated for: treatment of schizophrenia; treatment of bipolar disorder; add-on treatment of major depressive episodes in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - quetiapine - prolonged-release tablet - 200 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine - antipsychotics; diazepines, oxazepines, thiazepines and oxepines - it is indicated for: treatment of schizophrenia; treatment of bipolar disorder; add-on treatment of major depressive episodes in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - quetiapine - prolonged-release tablet - 300 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine - antipsychotics; diazepines, oxazepines, thiazepines and oxepines - it is indicated for: treatment of schizophrenia; treatment of bipolar disorder; add-on treatment of major depressive episodes in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - quetiapine - prolonged-release tablet - 400 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine - antipsychotics; diazepines, oxazepines, thiazepines and oxepines - it is indicated for: treatment of schizophrenia; treatment of bipolar disorder; add-on treatment of major depressive episodes in patients with major depressive disorder (mdd) who have had sub-optimal response to antidepressant monotherapy

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

stada arzneimittel gmbh, germany - bortezomib - solution for injection - 2.5 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

recordati rare diseases australia pty ltd - betaine, quantity: 1 g/g - powder, oral - excipient ingredients: - as an adjunct in the treatment of homocystinuria.